BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2025 9:26:55 AM | Browse: 146 | Download: 593
 |
Received |
|
2024-10-07 02:33 |
|
Peer-Review Started |
|
2024-10-10 01:49 |
|
First Decision by Editorial Office Director |
|
2024-11-08 06:05 |
|
Return for Revision |
|
2024-11-08 06:05 |
|
Revised |
|
2024-11-21 04:18 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-01-02 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-01-02 05:55 |
|
Articles in Press |
|
2025-01-02 05:55 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-01-13 03:40 |
|
Publish the Manuscript Online |
|
2025-01-21 09:26 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
From metabolic regulation to kidney protection: β-arrestin 2 as a dual-function therapeutic target
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jian Yang, Cheng-Zhi Zhang and Jing Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82471616, 82170418, 82271618 |
| Natural Science Foundation of Hubei Province |
2022CFA015 |
| Central Guiding Local Science and Technology Development Project |
2022BGE237 |
| Key Research and Development Program of Hubei Province |
2022BCE001, 2022DCC014, 2023BCB139 |
| Hubei Provincial Health Commission Project |
WJ2023M151 |
|
| Corresponding Author |
Jing Zhang, MD, Central Laboratory, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, No. 183 Yiling Avenue, Yichang 443003, Hubei Province, China. zhangjing@ctgu.edu.cn |
| Key Words |
Type 2 diabetes; Diabetic nephropathy; Βeta-arrestin 2; Βeta-arrestin 1; Metabolic regulation; Tissue-specific signaling; Therapeutic strategies; Multi-target therapies |
| Core Tip |
This article highlights the dual-function potential of β-arrestin 2 as a therapeutic target for both diabetic nephropathy and metabolic regulation. Recent findings by Liu et al demonstrated that β-arrestin 2 exacerbates kidney damage in diabetic nephropathy by promoting glomerular endothelial cell apoptosis via the endoplasmic reticulum stress pathway. Conversely, β-arrestin 2 plays a significant role in regulating metabolic processes, such as hepatic glucose production, insulin secretion, and adipose tissue function. Its tissue-specific effects make β-arrestin 2 a promising target for therapeutic strategies, with ongoing advancements in biased ligands, small molecule modulators, and RNA aptamers. |
| Publish Date |
2025-01-21 09:26 |
| Citation |
Yang J, Zhang CZ, Zhang J. From metabolic regulation to kidney protection: β-arrestin 2 as a dual-function therapeutic target. World J Diabetes 2025; 16(3): 102014 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i3/102014.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i3.102014 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
